Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial

Summary Aims We assessed the potential efficacy and safety of propagermanium (PG), an organic compound that inhibits the C–C chemokine receptor type 2, administration in patients with type 2 diabetes and nephropathy. Furthermore, we assessed the feasibility of future studies. Materials and methods W...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Akinori Hara, Miho Shimizu, Erika Hamaguchi, Hirokazu Kakuda, Kenzo Ikeda, Toshiya Okumura, Kiyoki Kitagawa, Yoshitaka Koshino, Motoo Kobayashi, Kazuya Takasawa, Yukimasa Hisada, Tadashi Toyama, Yasunori Iwata, Norihiko Sakai, Takashi Wada
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2020-07-01
coleção:	Endocrinology, Diabetes & Metabolism
Assuntos:	albuminuria CCR2 diabetes kidney MCP‐1 propagermanium
Acesso em linha:	https://doi.org/10.1002/edm2.159
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!